All In Biotech

Drug Trial Radar · NCT00444522

Staccato Alprazolam Single Dose PK

Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jun 2005

Primary completion

Aug 2005

Study completion Aug 2005

Sponsor

Lead sponsor
Alexza Pharmaceuticals, Inc.Not stated
Sponsor type
Not stated
First posted
Mar 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.

Conditions

  • Healthy

Interventions

  • Alprazolam thermal aerosolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic profile and dose proportionality

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.